Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: A case report

Journal of Periodontology

Volumn 75, Issue 4, 2004, Pages 613-619

  Sánchez, Andrés R ^a   Sheridan, Phillip J ^a   Rogers, Roy S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Graft versus host disease; Lichen planus therapy; Lichenoid eruptions therapy; Tacrolimus therapeutic use

Indexed keywords

CHLORHEXIDINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; GENGRAFT; LORAZEPAM; MARPEN VK; METHOTREXATE; METOPROLOL SUCCINATE; METRONIDAZOLE; MULTIVITAMIN; PAMIDRONIC ACID; PENICILLIN V; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; QUINAPRIL; RABEPRAZOLE; SIMVASTATIN; TACROLIMUS; TOPOROL; UNCLASSIFIED DRUG; VALACICLOVIR; WARFARIN;

ADULT; ARTICLE; BACTERIAL INFECTION; BULLOUS SKIN DISEASE; CARDIOMYOPATHY; CASE REPORT; COLITIS; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; GINGIVA BLEEDING; GRAFT VERSUS HOST REACTION; HEART ATRIUM FIBRILLATION; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPONATREMIA; IMMUNOFLUORESCENCE; IMMUNOPATHOLOGY; LICHEN PLANUS; LONG TERM CARE; LOW DRUG DOSE; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; OSTEOPENIA; PNEUMOCYSTIS PNEUMONIA; QT PROLONGATION; TREATMENT OUTCOME; VIRUS INFECTION;

ADMINISTRATION, TOPICAL; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; TACROLIMUS;

EID: 2442600159     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2004.75.4.613     Document Type: Article

References (71)

1. Snover DC. Acute and chronic graft versus host disease: histopathological evidence for two distinct pathogenetic mechanisms. Hum Pathol 1984;15:202-205.
2. Bennett JM. Kouides PA. Forman SJ. The myelodysplastic syndromes: Morphology, risk assessment, and clinical management. Int J Hematol 2002;76:228-238.
3. Hofmann WK. Koeffler HP. Important features of myelodysplastic syndrome. Int J Hematol 2002;76:222-227.
4. Luger S. Sacks N. Bone marrow transplantation for myelodysplastic syndrome - who? when? and which? Bone Marrow Transplant 2002;30:199-206.
5. Horn TD, Zahurak ML, Atkins D. Lichen-planus like histopathological characteristics in the cutaneous graft-vs-host reaction. Arch Dermatol 1997;133:961-965
6. Epstein JB, Gorsky M, Epstein MS, Nantel S. Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions: a series of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91:56-61.
7. Woo SB, Lee SJ, Schubert MM. Graft-vs-host disease. Crit Rev Oral Biol Med 1997;8:201-216.
8. Nakamura S, Hiroki A, Shinohara M, et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:556-563.
9. Eggleston TI, Ziccardi VB, Lumerman H. Graft-versus-host disease. Case report and discussion. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:692-696.
10. Johnson ML, Farmer ER. Graft-versus-host reactions in dermatology. J Am Acad Dermatol 1998;38:369-384.
11. Black MM. Lichen planus and lichenoid disorders. In: Champion RH, Burton DA, Breathnach SM, eds. Textbook of Dermatology, vol. 3, 6th ed. Oxford: Blackwell Science; 1998:1899-1925.
12. Andrews ML, Robertson I, Weedon D. Cutaneous manifestations of chronic graft-versus-host disease. Australas J Dermatol 1997;38:55-64.
13. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, MacDonald GB. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosupression. Blood 1981;57:267-276.
14. Heney D, Norfold DR, Wheeldon J, Bailey CC, Lewis IJ, Barnard DL. Thalidomide treatment of chronic graft-versus-host disease. Br J Haematol 1991;78:23-27.
15. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998;21:577-581.
16. Gaziev D. Galimberti M. Lucarelli G. Polchi P. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant 2000; 25:689-696.
17. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000;96:3995-996.
18. Gaziev D, Lucarelli G. Novel approaches to the treatment of chronic graft-versus-host disease. Expert Opin Investig Drugs 2001;10:909-923.
19. Moraes M, Russo G. Thalidomide and its dermatologic uses. Am J Med Sci 2001;321:321-326.
20. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7:265-273.
21. van de Poel MH, Pasman PC, Schouten HC. The use of thalidomide in chronic refractory graft versus host disease. Neth J Med 2001;59:45-49.
22. Volc-Platzer B, Hönigsmann H, Hinterberger W, et al. Photochemotherapy improves chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 1990;23:220-228.
23. Hönigsmann H, Fitzpatrick TB, Pathak MA, Wolf K. Oral photochemotherapy with psoralens and UVA (PUVA): principles and practice. In: Fitzpatrick TB, Eisen AZ, Wolf K, Freidberg IM, Auster KF, eds. Dermatology in General Medicine, 4th ed, vol. 1. New York: McGraw-Hill; 1993:1728-1754.
24. Jansin CT, Lehtinin R, Happonin R-P, Lehtinin A, Söderlund K. Mouth PUVA: New treatment for recalcitrant oral lichen planus. Photodermatol 1987;4:165-166.
25. Lundquist G, Fosgren H, Gajechi M, Emtestam L. Photochemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:554-458.
26. Keursilehto A, Lehtenin R, Happonin R-P, et al. An open clinical trial of a new mouth-PUVA variant in the treatment of oral lichenoid lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:502-505.
27. Volgelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralin (PUVA). Bone Marrow Transplant 1996;17:1061-1067.
28. Redding SW, Callander NS, Haveman CW, Leonard DL. Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86: 183-187.
29. Jampel RM, Farmer ER, Vogelsang GB, Wingard J, Santos GW, Morison WL. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol 1991;127: 1673-1678.
30. Atkinson K, Weller P, Ryman W, Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986;1:227-236.
31. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996;348: 1240-1241.
32. Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998;102:555-557.
33. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998;102:637-644.
34. Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000;47:436-440.
35. Jegasothy BV, Ackerman CD, Todo S, et al. Tacrolimus (FK 506) - A new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992;128:781-785.
36. Lener EV, Brieva J, Schachter M, et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 2001;137:419-422.
37. Rozycki TW, Rogers RS III, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: A series of 13 patients. J Am Acad Dermatol 2002;46:27-34.
38. Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002;46:35-41.
39. Morrison L, Kratochvil FJ, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002;47:617-620.
40. Olivier V, Lacour JP, Mousnier A, Garraffo R, Monteil RA, Ortonne JP. Treatment of erosive oral lichen planus with low concentrations of topical tacrolimus. Arch Dermatol 2002;138:1335-1338.
41. Jubran RF, Dinndorf PA. Successful therapy of refractory graft versus host disease with tacrolimus and psoralen plus ultraviolet light. Ther Drug Monit 1998;20:236-239.
42. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-versus-host disease. Arch Dermatol 2001;137:1202-1206.
43. Kina T, Hatanaka H, Hashimoto M. FK506, a novel immunosuppressant isolated from Streptomyces, I. J Antibiot 1987;40:1249-1255.
44. Kina T, Hatanaka H, Hashimoto M. FK506, a novel immunosuppressant isolated from Streptomyces, II. J Antibiot 1987;40:1256-1265.
45. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive, FK506: In vitro effect on cloned T-cell activation. J Immunol 1987;139:1797-1803.
46. Schreiber SL, Crabtree GR. The mechanism of action cyclosporine A and FK506. Immunol Today 1992;13: 136-142.
47. Ahmad S. Lovastatin: Warfarin interaction. Arch Intern Med 1990;150:2407.
48. Koduri PR. Simvastatin and thrombotic thrombocytopenic purpura. [Letter]. Lancet 1998;352:2020.
49. Mogyorosi A, Bradley B, Showalter A, Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999;246:599-602.
50. Groneberg DA, Barkhuizen A, Jeha T. Simvastatin-induced thrombocytopenia. [Letter]. Am J Hematol 2001; 67:277.
51. Tsoi M-S. Immunological mechanisms of graft-versus-host syndrome in man. Transplantation 1982;33:459-464.
52. Sullivan KM, Parkman R. The pathophysiology and treatment of graft-versus-host disease. Clin Haematol 1983; 12:775-789.
53. Schubert MM, Sullivan KM, Morton TH, et al. Oral manifestations of chronic graft-vs-host disease. Arch Intern Med 1984;144:1591-1595.
54. Hitchins L, Fucich LF, Freeman SM, Millikan LE, Marrogin AJ. Immunophenotyping as a diagnostic tool to differentiate lichen planus from chronic graft-versus-host disease: Diagnostic observations on two patients. J Invest Med 1997;45:463-468.
55. Shulman HM, Sale GE, Lerner KG, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978;91:545-570.
56. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69: 204-217.
57. McDonald GB, Sullivan KM, Schuffler MD, Shulman HM, Thomas ED. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterol 1981;80: 914-921.
58. Sale GE, Shulman HM, Schubert MM, et al. Oral and ophthalmic pathology of graft versus host disease in man: Predictive value of the lip biopsy. Hum Pathol 1981; 12:1022-1030.
59. Saurat JH, Didier-Jean L, Gluckman E, Bussel A. Graft versus host reaction and lichen planus-like eruption in man. Br J Dermatol 1975;92:591-592.
60. Saurat JH, Gluckman E, Bussel A, Didier-Jean L, Puissant A. The lichen planus-like eruption after bone marrow transplantation. Br J Dermatol 1975;92:675-681.
61. Saurat JH, Gluckman E. Lichen planus-like eruption following bone marrow transplantation: a manifestation of the graft-vs-host disease. Clin Exp Dermatol 1977;2: 335-344.
62. Rodu B, Gockerman JP. Oral manifestations of the chronic graft-vs-host reaction. JAMA 1983;249:504-507
63. Pagliaro JA, White S, Strutton G, Guerin D. Lichen planus-like eruption following autologous bone marrow transplantation for chronic myeloid leukaemia. Australas J Dermatol 2001;42:188-191.
64. Medina JE, Frame R, Toth B. Head and neck manifestations of the chronic graft-vs-host disease. Laryngoscope 1984;94:1145-1152.
65. Argiriadou AS, Sardella A, Demarosi F, Carrasi A. Gingival lesions in a patient with chronic oral graft-versus-host disease: a case report. J Clin Periodontol 2003;30: 375-278.
66. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmadg K, Starzl TE. Tacrolimus (FK506): a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992;128:781-785.
67. Koga T, Yano T, Ichigawa Y, Oizumi K, Mochizuki M. Pulmonary infiltrates recovered by FK506 in a patient with Behcet's disease. Chest 1993;104:309-311.
68. Abu-Elmagd K, Jegasothy BV, Ackerman CD. Efficacy of FK506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc 1991;23:3328-3329.
69. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997;92:876-879.
70. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millenium? Arch Dermatol 1999;135: 574-580.
71. Rogers RS III, Eisen D. Erosive oral lichen planus with genital lesions: the vulvovaginal-gingival syndrome and the peno-gingival syndrome. Dermatol Clin 2003;21: 91-99.